Patients undergoing transcatheter atrial septal defect (ASD) closure did not have worsening migraines after completing a course of dual antiplatelet therapy, the CANOA investigators found. Overall, ...
Three months of clopidogrel is sufficient to curb new-onset migraine headaches after percutaneous atrial septal defect (ASD) closure, new data from the randomized CANOA trial show. There was no ...
Initial data looking at safety and efficacy of an interatrial septal occluder with a bioresorbable frame show promise for closing atrial septal defects (ASDs), but the study authors suggest a redesign ...
Evidence-based recommendations on transcatheter endovascular closure of perimembranous ventricular septal defect. This involves inserting a small blocking device (called an occluder) into the heart.
BAAR, Switzerland and SANTA CLARA, Calif., Feb. 8, 2022 /PRNewswire/ -- atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal ...
It remains early days for transcatheter mitral-valve replacement (TMVR) as a minimally invasive way to treat severe, mitral regurgitation (MR), but it's even earlier days for TMVR as an endovascular ...
Current evidence on the safety and efficacy of transcatheter endovascular closure of perimembranous ventricular septal defect (VSD) is adequate to support the use of this procedure provided that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results